Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin

Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin

Show other versions (1)

Background: Topiroxostat, an inhibitor of xanthine oxidoreductase (XOR) was shown to reduce urinary albumin excretion of hyperuricemic patients with chronic kidney disease. However, its pharmacological mechanism is not well understood. In this study, we examined the effects of topiroxostat on glomer...

Full description

Bibliographic Details
Main Authors: Ying Zhang, Yoshiyasu Fukusumi, Mutsumi Kayaba, Takashi Nakamura, Ryusuke Sakamoto, Naoki Ashizawa, Hiroshi Kawachi
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Nefrología (English Edition)
Subjects:
Topiroxostat
Prolongaciones en forma de pie de podocitos
Diafragma de hendidura
Nefrina
Podoplanina
Online Access:http://www.sciencedirect.com/science/article/pii/S2013251421001139

Similar Items

Similar Items